Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2000

View Archived Issues

AstraZeneca commences phase III trial of Seroquel for treatment of bipolar disorder

Bristol-Myers Squibb and ICAgen to continue collaboration for atrial fibrillation

Buccal formulation of insulin will be developed by Lilly and Generex

Lupus therapy candidate granted orphan drug designation

BASF grants exclusive licenses for oncolytic compounds to Ilex

Low-dose nifekalant safely suppresses ventricular arrhythmias following AMI

Full, selective 5-HT1A antagonist characterized as having potential in depression, smoking cessation

SDZ-RAD continues to shine as a potential agent for transplantation

FR-167653 exerts beneficial effects in rat model of ischemia/reperfusion liver injury

NO donor FK-409 protects against ischemia/reperfusion injury of small intestine

HGS advances clinical development of novel protein

Antihypertensive activity demonstrated for new vasopressin receptor antagonists in rats

SRI presents novel steroid mimics useful for breast cancer

Pyrazoles as selective CB2 receptor modulators patented by SmithKline Beecham

Gaucher's disease treatment shows continued efficacy after 18 months

Synthesis and activity of novel PTK inhibitors reported by U.S. university researchers

Long-term, once-a-day efficacy demonstrated by HAART regimen including Coviracil

Canadian lab designs 5-ht6 receptor antagonists for schizophrenia

Crohn's disease therapy effective and safe in phase II trial

New antibiotics emerging from Pfizer R&D

Priority review granted to Femara as first-line breast cancer therapy

Several series of inhibitors of VLA-4-mediated cell adhesion from Elan covered by patents

Phase I clinical trials of Xcytrin begin for treatment of NSCLC and glioblastoma multiforme

C5 inhibitor receives fast track status for use in cardiopulmonary bypass

NCI sponsors additional phase II studies of Prostvac VF vaccine

DNA vaccine encoding C3d enhances immune response to influenza

Researchers uncover protein key to the development of Alzheimer's

Metformin completely reverses fatty liver in mouse model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...